Published: Jun 26, 2026
Written by Klarity Editorial Team
Published: Jun 26, 2026

You’ve probably noticed it in your patient panels: the quiet question about ‘that weight-loss shot everyone’s talking about,’ or the frustration from someone who’s gained 40 pounds on their antipsychotic. Maybe you’ve had a colleague mention they’re now prescribing semaglutide, or you’ve seen ads for telehealth weight-loss platforms offering $300+ per consult.
The numbers are real: by late 2025, an estimated 20 million Americans were actively taking GLP-1 medications like Ozempic or Wegovy — a 600% increase in weight-loss usage over just six years. And here’s the interesting part for psychiatrists: nearly half of psychiatrists surveyed in major academic departments reported they’re already prescribing or recommending these medications, often to address medication-induced weight gain or co-morbid obesity.
This isn’t some random side hustle. It’s a legitimate clinical opportunity that plays directly to psychiatry’s strengths: understanding behavior change, managing chronic treatments, and addressing the psychological aspects of health that most weight-loss clinics ignore entirely.
But here’s the reality check: scaling a GLP-1 practice without drowning in admin work, patient volume, or compliance headaches requires intentional strategy. Let’s talk about how to actually do this — the patient acquisition, the workflows, the economics, and most importantly, how to avoid burning out while building something sustainable.
The Patient Overlap You Already Have
Start by looking at your current caseload. How many patients are on medications known for weight gain? Antipsychotics, mood stabilizers, mirtazapine, certain SSRIs — the list is long, and the frustration is real. These patients aren’t asking for vanity prescriptions; they’re dealing with a iatrogenic problem that affects their self-esteem, physical health, and often their willingness to stay on psychiatric medications.
By offering GLP-1 treatment, you’re not pivoting to a completely different specialty — you’re addressing a legitimate medical complication of the care you’re already providing. This integrated approach resonates with patients who feel like their mental and physical health are finally being treated as connected, not siloed.
Beyond medication side effects, there’s significant overlap between psychiatric conditions and obesity. Binge eating disorder, emotional eating tied to depression or anxiety, the metabolic effects of chronic stress — these are all in psychiatry’s wheelhouse. Unlike a nurse practitioner working for a generic telehealth weight-loss mill, you bring actual expertise in the behavioral and mental health components that determine whether patients succeed long-term.
What the Market Actually Looks Like
The demand is overwhelming the supply. With roughly 75% of Americans overweight or obese and only a few thousand board-certified obesity medicine specialists nationwide, there’s a massive access gap. Tens of thousands of new patients start GLP-1 treatments every week, and many can’t access specialized obesity clinics or don’t want to wait months for an appointment.
This creates an unusual opportunity: relatively little competition, especially in telehealth. Yes, there are startups and cash-pay clinics everywhere now, but most are staffed by providers with no mental health training. When patients search for ‘psychiatrist GLP-1’ or ‘weight loss medication for depression patients,’ there’s often nobody ranking for those terms in their area.
The cash-pay economics make this even more attractive. While insurance coverage for GLP-1s remains limited (only 13 state Medicaid programs covered them for weight loss as of late 2024), patients are often willing to pay out-of-pocket for these ‘life-changing’ medications. Monthly consultation fees typically range from $99-$299, and if you’re operating through a platform or with good conversion, you can fill your practice faster than traditional psychiatric patient acquisition — which brings us to the business model question.
Let’s be honest about what patient acquisition actually costs and how the economics work, because this is where a lot of providers get misled by overly optimistic projections.
DIY Marketing: The Hidden Costs
If you decide to market a GLP-1 service independently — through your own website, Google Ads, or directory listings — understand the real numbers. Acquiring a qualified psychiatric patient through DIY channels typically costs $200-500+ per patient when you factor in everything:
The bottom line: most solo providers don’t have the expertise, patience, or $3,000-5,000/month budget to make DIY marketing work efficiently. It can eventually be cost-effective if you stick with it long enough and know what you’re doing — but that’s a big ‘if.’
The Platform Economics Alternative
This is where platforms like Klarity Health change the math entirely. Instead of gambling thousands on marketing channels with uncertain results, you pay only when a qualified patient actually books with you — a standard listing fee per new patient lead, similar to how Zocdoc works.
Here’s why this model makes economic sense for most providers, especially those starting out or scaling:
Think about it this way: if you spend $5,000 on marketing over three months and acquire 10 patients, that’s $500 per patient — and you paid it all upfront with no guarantee of results. With a pay-per-appointment model, you pay that same amount (or often less) but only when you actually see the patient. That’s guaranteed ROI versus gambling.
The key is treating this as a patient acquisition cost, not an expense. If that new GLP-1 patient generates $200-300 per month in consultation revenue and stays for an average of 12 months, the lifetime value is $2,400-3,600. Paying a one-time acquisition fee to access that patient makes perfect business sense.
State Licensure and Scope of Practice
The regulatory landscape for GLP-1 prescribing via telehealth is straightforward in one sense and complex in another. The good news: GLP-1 medications are not controlled substances, which means the Ryan Haight Act’s in-person exam requirement doesn’t apply. You can legally prescribe semaglutide or tirzepatide to patients via telemedicine without ever meeting them face-to-face, as long as you meet standard-of-care requirements.
The complexity comes from state-specific rules:
For Psychiatrists (MD/DO): You simply need a medical license in the patient’s state. If you’re in California treating California patients, you need a CA license. Some states (like Florida) offer special out-of-state telehealth registrations for physicians, which can expand your reach without full licensure. Texas, Illinois, and Pennsylvania are members of the Interstate Medical Licensure Compact (IMLC), which can expedite multi-state licensing if you want to practice across state lines.
For PMHNPs: This gets more complicated because nurse practitioner scope varies wildly by state:
If you’re an NP in a restricted state, you’ll need to either partner with a supervising physician or work through a platform that provides that supervision structure.
The Standard of Care for Telehealth GLP-1 Prescribing
Regardless of state, you need to conduct a proper clinical evaluation. This means:
Create standardized intake forms and checklists to ensure consistency. Many telehealth practices use an ‘Obesity Intake Panel’ order set that can be clicked with one button — this saves time and ensures nothing gets missed.
One often-overlooked aspect: monitoring for psychiatric side effects. There were reports in 2023 about possible suicidal ideation linked to GLP-1s, though by 2026 the FDA reviewed data and found no clear causal link. Still, as a psychiatrist, you should routinely ask about mood changes during follow-ups — this is a value-add that distinguishes you from generic weight-loss providers.
Here’s where most providers fail: they add GLP-1 patients to their existing psychiatric practice without redesigning their workflow, and within three months they’re drowning in follow-up appointments and lifestyle counseling questions.
The Three-Phase System
Phase 1: Intensive Initiation (Month 1-3)New GLP-1 patients need more frequent touchpoints early on:
Phase 2: Stable Maintenance (Month 4-12)Once patients are on a stable dose and losing weight predictably:
Phase 3: Long-term Management (12+ months)Patients at goal weight or on maintenance dose:
The key insight: these phases require different levels of provider involvement. You can’t sustain doing 45-minute diet counseling sessions with every patient every month. That’s where delegation comes in.
Delegation Strategy
Build a team structure that takes non-prescribing work off your plate:
For example: Instead of spending 20 minutes every visit discussing meal planning with each patient, your dietitian runs a monthly group telehealth session covering common topics (managing nausea, protein targets, eating out). Patients get better support, and you’ve just saved yourself 10+ hours per month.
Technology That Actually Saves Time
Invest in tools that reduce manual work:
One psychiatrist I know cut her average GLP-1 follow-up visit from 25 minutes to 12 minutes just by implementing pre-visit questionnaires and having her MA document the basics before she joined the call. That freed up 6-8 appointment slots per week.
The irony of scaling a successful practice is that success itself can destroy you if you’re not careful. Here’s what actually matters:
Cap Your Volume Intentionally
Don’t let patient demand dictate your schedule. Decide in advance: ‘I’ll see 10 new GLP-1 consults per week, with 15 follow-ups.’ When you hit that limit, new patients go on a waitlist or you raise your prices. This prevents the endless treadmill of ‘just one more patient.’
Maintain Schedule Control
Research shows that greater schedule control and virtual practice options significantly reduce provider burnout. Telehealth gives you flexibility — use it. Block out admin time, lunch breaks, and early Friday afternoons. Set specific hours for patient communication (e.g., ‘I respond to messages between 12-2pm’) and use delayed delivery or an answering service for after-hours.
Mix Your Patient Types
If you’re doing both psychiatric and weight-management work, schedule variety into your day. Alternate between complex psychiatric cases and straightforward GLP-1 follow-ups. Many providers find this mix more engaging than pure specialty work — it keeps your skills sharp and prevents monotony.
Build in Support Structures
Join peer communities (obesity medicine interest groups, telehealth clinician forums) where you can discuss challenges and learn from others’ workflows. Consider formal obesity medicine CME or certification — not just for credentials, but because the education reduces uncertainty-driven stress.
Monitor Your Own Metrics
Track your own well-being as closely as patient outcomes. Are you working evenings regularly? Feeling emotionally exhausted? Dreading certain types of appointments? These are early warning signs. When they appear, adjust: hire more support staff, reduce new patient intake temporarily, or delegate additional tasks.
Most GLP-1 telehealth practices favor cash-pay models for good reason: insurance coverage for obesity medications remains limited, and the reimbursement headaches aren’t worth it for many providers.
The Cash-Pay Case
Pros:
Typical cash-pay structure:
The challenge: You’re limiting your market to patients who can afford out-of-pocket costs, which excludes many who might benefit most.
The Insurance Case
Pros:
Cons:
The Hybrid Approach
Many smart providers split the difference:
Be transparent with patients upfront about costs. Calculate their all-in monthly expense: consultation fees + medication costs (brand-name Wegovy is $1,300+ without coverage; compounded semaglutide runs $200-400). This prevents sticker shock and builds trust.
Each state has quirks that affect how you operate:
California: Requires patient consent for telehealth (document it). Medi-Cal started covering GLP-1s for obesity in 2024, which may increase insured patient demand. Large, diverse market with high interest in metro areas but also underserved rural populations. NPs gain independence starting 2026 if they meet the AB 890 requirements.
Texas: Strict NP supervision requirements (collaborative agreement mandatory). IMLC member for physicians, which eases multi-state licensing. High obesity rate (~35%) and many rural areas = strong demand but fewer autonomous NP options. Telemedicine explicitly allowed without in-person visit requirement.
Florida: Out-of-state physicians can get telehealth registration (great for multi-state practices). NPs need physician oversight unless they’re primary care specialists. Large retirement population interested in health improvement, but limited Medicaid coverage means mostly cash-pay patients.
New York: Experienced NPs (3,600+ hours) can practice independently, expanding the provider pool. Huge population but competitive market in NYC. Upstate and rural areas face shortages. Good opportunity to partner with hospital systems addressing antipsychotic-induced weight gain.
Pennsylvania: NPs require physician collaborative agreements (no independent practice yet). Joined IMLC and Nurse Licensure Compact, easing some multi-state practice. Mix of urban and rural patients; Medicaid started covering GLP-1s in 2024.
Illinois: NPs can achieve Full Practice Authority after 4,000 hours + additional education. IMLC member for physicians. Strong telehealth parity law for insurance coverage. Medicaid covers GLP-1s for obesity. Academic centers in Chicago leave community practice gaps elsewhere.
Here’s the honest assessment: Adding GLP-1 services to your psychiatric practice can be financially rewarding (patient demand is real, acquisition costs are manageable through the right channels, and cash-pay economics work) and clinically meaningful (you’re addressing a genuine health problem for patients who often have limited options).
But it only works if you approach it strategically:
The providers who succeed with this are the ones who see it as an extension of psychiatric care, not a completely separate business. They’re treating the whole patient — mental health, metabolic health, behavior change — and leveraging psychiatry’s unique strengths in an area where demand far exceeds supply.
If you’re interested in exploring how telehealth platforms can connect you with qualified GLP-1 patients without the marketing headaches, Klarity Health’s provider network offers a pay-per-appointment model that eliminates upfront risk and provides the infrastructure to scale sustainably.
Can psychiatrists legally prescribe GLP-1 medications like Ozempic or Wegovy?
Yes. Psychiatrists (MD/DO) have full prescriptive authority for GLP-1 medications in all states where they hold a medical license. These medications are not controlled substances, so there are no additional DEA requirements beyond your standard prescribing privileges. Psychiatric NPs can also prescribe them in most states, though scope-of-practice rules vary (some states require physician collaboration agreements).
Do I need to see patients in person before prescribing GLP-1 medications via telehealth?
No. Because GLP-1 medications are not controlled substances, the Ryan Haight Act’s in-person examination requirement doesn’t apply. You can establish a valid patient relationship and prescribe these medications entirely through telemedicine, as long as you conduct an appropriate clinical evaluation via video (or audio where state law permits) and meet the standard of care for your state. Most states explicitly allow this for non-controlled medications.
How much does it actually cost to acquire a new GLP-1 patient?
The real all-in cost for DIY patient acquisition typically runs $200-500+ per patient when you account for agency fees, ad spend, staff time qualifying leads, and no-show rates. SEO takes 6-12 months before generating meaningful patient flow, and Google Ads for weight-loss keywords cost $15-40+ per click with conversion rates that mean you’re paying $200-400+ per booked patient. Platform models like Klarity charge a standard listing fee per new patient lead, which eliminates upfront spend and provides pre-qualified patients — often more cost-effective than DIY marketing.
What’s the typical revenue potential from a GLP-1 patient?
In cash-pay models, initial consultations typically run $199-$299, with monthly follow-ups at $99-$149. Average patient retention is 8-12 months, making lifetime value $1,200-$2,400+ per patient in consultation fees alone. Some practices charge subscription fees ($299/month including consultations and compounded medication), which can generate $3,000-4,000+ per patient annually. Insurance-based models generate lower per-visit revenue but potentially higher volume through broader access.
How do I manage patient load without burning out?
Successful scaling requires three elements: (1) Delegation — use MAs/RNs for data gathering, health coaches for lifestyle counseling, and group sessions for common education topics; (2) Technology — templated documentation, remote patient monitoring, and asynchronous check-ins for stable patients; (3) Boundaries — cap new patient intake, set specific communication hours, and schedule admin time. Research shows that schedule control and flexible telehealth practice significantly reduce burnout compared to traditional high-volume models.
Should I offer GLP-1 services on a cash-pay or insurance basis?
Most telehealth GLP-1 practices favor cash-pay because: insurance coverage for obesity medications remains limited (only 13 state Medicaid programs covered them as of 2024), prior authorization burdens are substantial, and patients often pay out-of-pocket for medications anyway. However, a hybrid approach works well — charge cash for comprehensive initial evaluations, bill insurance for follow-up visits where coverage exists, and help patients navigate pharmacy benefits. The key is transparency about total monthly costs (consultations + medications) upfront.
What are the most common compliance mistakes providers make?
The top three: (1) Inadequate documentation of medical necessity (failing to document BMI, comorbidities, previous weight-loss attempts); (2) Not obtaining proper informed consent for off-label use (like prescribing Ozempic for obesity rather than diabetes); (3) Using unvetted compounding pharmacies that may not meet FDA quality standards. Also watch for state-specific requirements like California’s mandate for telehealth consent documentation.
How do I handle psychiatric side effects like mood changes on GLP-1s?
This is where psychiatrists have a clear advantage. While the FDA found no causal link between GLP-1s and suicidal ideation after reviewing data through 2026, you should routinely screen for mood changes at every follow-up. Use standardized questions: ‘Have you noticed any changes in your mood, anxiety, or sleep since starting/increasing the medication?’ Document responses and adjust care accordingly. Your mental health expertise is a differentiator — patients value having a prescriber who understands the psychological aspects of weight loss.
Can I prescribe to patients in multiple states?
Yes, but you need a medical license in each state where your patients are located. Some states (Florida) offer special out-of-state telehealth registrations for physicians. The Interstate Medical Licensure Compact (IMLC) — which includes Texas, Illinois, Pennsylvania, and others — provides expedited licensure processes for physicians wanting to practice in multiple member states. NPs face additional complexity with varying scope-of-practice rules and collaborative agreement requirements by state.
What do I tell patients about medication costs and insurance coverage?
Be upfront and realistic. Brand-name Wegovy typically costs $1,300+ per month without insurance coverage. Compounded semaglutide from quality pharmacies runs $200-400/month. While most insurance covers GLP-1s for diabetes, coverage for obesity is limited — patients should check with their specific plan. Help them understand the total monthly investment (consultation fees + medication costs) before starting treatment. This transparency builds trust and reduces dropout from sticker shock later.
Axios. ‘Just how many Americans are taking GLP-1s now.’ May 27, 2025. Available at: https://www.axios.com/2025/05/27/american-glp1-use-weight-loss-increasing
ConfectioneryNews. ‘GLP-1 drugs like Ozempic are reshaping health, diet and the food industry.’ October 20, 2025. Available at: https://www.confectionerynews.com/Article/2025/10/20/glp-1-drugs-like-ozempic-are-reshaping-health-diet-and-the-food-industry
Time Magazine. ‘The Heavy Cost of Using Weight-Loss Drugs to Get Skinny.’ August 22, 2025. Available at: https://time.com/7311517/cost-weight-loss-drugs-skinny
Axios. ‘America’s doctors need more obesity medicine training.’ May 28, 2024. Available at: https://www.axios.com/2024/05/28/us-doctors-obesity-health-care-training
Axios. ‘States slow to cover GLP-1s for weight loss.’ November 5, 2024. Available at: https://www.axios.com/2024/11/05/states-slow-to-cover-glp-1s-for-weight-loss
Find the right provider for your needs — select your state to find expert care near you.